[1]
|
Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T. and Veesler, D. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181, 281-292.e6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102599 https://doi.org/10.1016/j.cell.2020.02.058
|
[2]
|
Zhang, H., Penninger, J.M., Li, Y., Zhong, N. and Slutsky, A.S. (2020) Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target. Intensive Care Medicine, 46, 586-590. https://doi.org/10.1007/s00134-020-05985-9
|
[3]
|
Thachil, J., Tang, N., Gando, S., et al. (2020) ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 18, 1023-1026. https://doi.org/10.1111/jth.14810
|
[4]
|
Marietta, M., Ageno, W., Artoni, A., et al. (2020) COVID-19 and Haemostasis: A Position Paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus, 18, 167-169.
|
[5]
|
GFHT/GIHP (2020) Proposition pour le traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec COVID-19. https://site.geht.org/docutheque
|
[6]
|
Patell, R., Bogue, T., Koshy, A.G., Bindal, P., Merrill, M., Aird, W.C., et al. (2020) Post-Discharge Thrombosis and Hemorrhage in Patients with COVID-19. Blood, 136, 1342-1346. https://doi.org/10.1182/blood.2020007938
|
[7]
|
Zuily, S., Dufrost, V. and Wahl, D. (2020) Thrombose artérielle et veineuse au cours du COVID-19. Archives des Maladies du Coeur et des Vaisseaux—Pratique, 2020, 16-19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413116 https://doi.org/10.1016/j.amcp.2020.08.003
|
[8]
|
Fogarty, H., Townsend, L., Ni, C.C., Bergin, C., Martin-Loeches, I., Browne, P., et al. (2020) COVID-19 Coagulopathy in Caucasian Patients. British Journal of Haematology, 189, 1044-1049. https://doi.org/10.1111/bjh.16791
|
[9]
|
Levi, M., Thachil, J., Iba, T. and Levy, J.H. (2020) Coagulation Abnormalities and Thrombosis in Patients with COVID-19. The Lancet Haematology, 7, E438-E440.
|
[10]
|
Leisman, D.E., Deutschman, C.S. and Legrand, M. (2020) Facing COVID-19 in the ICU: Vascular Dysfunction, Thrombosis, and Dysregulated Inflammation. Intensive Care Medicine, 46, 1105-1108. https://doi.org/10.1007/s00134-020-06059-6
|
[11]
|
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. (2020) COVID-19: Consider Cytokine Storm Syndromes and Immuno-Suppression. The Lancet, 395, 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
|
[12]
|
Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Ander-Matt, R., Zinkernagel, A.S., et al. (2020) Endothelial Cell Infection and Endotheliitis in COVID-19. The Lancet, 395, 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
|
[13]
|
Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Merdji, H., et al. (2020) High Risk of Thrombosis in Patients in Severe SARS-CoV-2 Infection: A Multicenter Prospective Cohort Study. Intensive Care Medicine, 46, 1089-1098. https://doi.org/10.1007/s00134-020-06062-x
|
[14]
|
Yan, S.F., Mackman, N., Kisiel, W., Stern, D.M. and Pinsky, D.J. (1999) Hypoxia/Hypoxemia-Induced Activation of the Procoagulant Pathways and the Pathogenesis of Ischemia-Associated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 2029-2035. https://doi.org/10.1161/01.ATV.19.9.2029
|
[15]
|
Gupta, N., Zhao, Y.-Y. and Evans, C.E. (2019) The Stimulation of Thrombosis by Hypoxia. Thrombosis Research, 181, 77-83. https://doi.org/10.1016/j.thromres.2019.07.013
|
[16]
|
Tignanelli, C.J., et al. (2020) Antihypertensive Drugs and Risk of COVID-19? The Lancet Respiratory Medicine, 8, e30-e31. http://www.thelancet.Com/respiratory
|
[17]
|
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet (London, England), 395, 507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
|
[18]
|
Tang, N., Li, D., Wang, X. and Sun, Z. (2020) Abnormal Coagulation Parameters Are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia. Journal of Thrombosis and Haemostasis, 18, 844-847. https://doi.org/10.1111/jth.14768
|
[19]
|
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet (London, England), 395, 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
|
[20]
|
Amin, A.N., Varker, H., Princic, N., Lin, J., Thompson, S. and Johnston, S. (2012) Duration of Venous Thromboembolism Risk across a Continuum in Medically Ill Hospitalized Patients. Journal of Hospital Medicine, 7, 231-238. https://doi.org/10.1002/jhm.1002
|
[21]
|
Samama, M.M., Cohen, A.T., Darmon, J.Y., Desjardins, L., Eldor, A., Janbon, C., et al. (1999) A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. New England Journal of Medicine, 341, 793-800. https://doi.org/10.1056/NEJM199909093411103
|
[22]
|
Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., et al. (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 149, 315-352. https://doi.org/10.1016/j.chest.2015.11.026
|
[23]
|
Hull, R.D., Schellong, S.M., Tapson, V.F., Monreal, M., Samama, M.-M., Nicol, P., et al. (2010) Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients with Recently Reduced Mobility: A Randomized Trial. Annals of Internal Medicine, 153, 8-18. https://doi.org/10.7326/0003-4819-153-1-201007060-00004
|
[24]
|
Cohen, A.T., Spiro, T.E., Büller, H.R., Haskell, L., Hu, D., Hull, R., et al. (2013) Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 368, 513-523. https://doi.org/10.1056/NEJMoa1111096
|